Answers are grounded in this paper and cite their sources.
Objective: To identify clinical and histological predictors of the need for treatment intensification (TI) in patients with newly diagnosed lupus nephritis (LN). Methods: Thirty-seven patients with biopsy-proven lupus nephritis diagnosed between 2015 and 2023 were included. Patients were stratified into those receiving standard therapy (steroids and mycophenolate mofetil) and those requiring treatment intensification (addition of calcineurin inhibitors, belimumab or other therapies). Treatment intensification predictors and complete and partial remission rates were assessed over 104 weeks. Results: Treatment intensification was necessary in 51.4% of patients. Proteinuria at 12 weeks (p = 0.008) and chronicity index in the biopsy (p = 0.02) were associated with treatment intensification in the univariate analysis. An exploratory multivariable logistic regression in the subgroup with chronicity index available (n=24) showed associations of 12-week proteinuria (OR 6.016; 95% Confidence Interval: 1.284–114.742, p = 0.014), and lower chronicity index (OR 0.518; 95% Confidence Interval 0.107–0.937, p = 0.024) with treatment intensification. The overall response rate (Complete + partial remission) reached 91.4% at 104 weeks. Steroids were successfully withdrawn in 29.7% of patients by week 104. Conclusion: Within a real-world cohort of patients with lupus nephritis, a low-risk subgroup – characterized by early proteinuria reduction and higher chronicity index on initial biopsy– may be suitable for management with dual therapy alone, although this hypothesis requires confirmation in larger prospective cohorts. Close monitoring of 12-week proteinuria and histological indices may help identify high-risk patients who require triple therapy intensification.
No takes yet. Share an insight, caveat, or question.
Hernandez-Velasco et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: